RGNX Stock Overview
A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
REGENXBIO Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.02 |
| 52 Week High | US$28.80 |
| 52 Week Low | US$11.43 |
| Beta | 1.34 |
| 11 Month Change | -19.44% |
| 3 Month Change | -44.53% |
| 1 Year Change | -34.74% |
| 33 Year Change | -69.16% |
| 5 Year Change | -76.38% |
| Change since IPO | -60.53% |
Recent News & Updates
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
Jun 11REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
May 11
Recent updates
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
Jun 11REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
May 11REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Apr 25Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Mar 11Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers
Mar 07Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified
Mar 05Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 02Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
Jan 19There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues
Dec 21We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully
Nov 09Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?
Aug 08REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 11Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation
May 08Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be
Mar 05REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration
Oct 03Regenxbio: A Transformative Year
Sep 15Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development
Aug 29Regenxbio to seek FDA's accelerated approval for Hunter Syndrome treatment, shares rise 8%
Aug 03Regenxbio: Patience And Regular Homework Are Keys
Jul 12Shareholder Returns
| RGNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.3% | 0.06% | 0.1% |
| 1Y | -34.7% | 9.9% | 24.1% |
Return vs Industry: RGNX underperformed the US Biotechs industry which returned 9.9% over the past year.
Return vs Market: RGNX underperformed the US Market which returned 24.1% over the past year.
Price Volatility
| RGNX volatility | |
|---|---|
| RGNX Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: RGNX's share price has been volatile over the past 3 months.
Volatility Over Time: RGNX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 344 | Ken Mills | www.regenxbio.com |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
REGENXBIO Inc. Fundamentals Summary
| RGNX fundamental statistics | |
|---|---|
| Market cap | US$592.06m |
| Earnings (TTM) | -US$260.15m |
| Revenue (TTM) | US$86.73m |
6.8x
P/S Ratio-2.3x
P/E RatioIs RGNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGNX income statement (TTM) | |
|---|---|
| Revenue | US$86.73m |
| Cost of Revenue | US$262.98m |
| Gross Profit | -US$176.25m |
| Other Expenses | US$83.90m |
| Earnings | -US$260.15m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.28 |
| Gross Margin | -203.23% |
| Net Profit Margin | -299.97% |
| Debt/Equity Ratio | 21.3% |
How did RGNX perform over the long term?
See historical performance and comparison